Anlon Healthcare to Acquire up to 32.52% in Apiqo Organics, 43.33% in Bizotic Lifescience via Share Swap
Anlon Healthcare Limited will acquire up to 32.52% of Apiqo Organics and 43.33% of Bizotic Lifescience via share swap. The total consideration is approximately ₹1,533 crore (₹1,165 crore for AOPL and ₹368 crore for BLPL) through preferential allotment of equity shares. The acquisitions are expected to be completed within 90 days.
The acquisitions represent a significant strategic move for Anlon Healthcare, involving substantial share issuances and aiming to strengthen its market position and supply chain.
The company is undertaking strategic acquisitions to enhance its business operations and shareholder value through share swap agreements.
Anlon Healthcare Limited has executed Share Swap Agreements to acquire up to 32.52% of Apiqo Organics Private Limited (AOPL) and up to 43.33% of Bizotic Lifescience Private Limited (BLPL). The acquisitions will be conducted through the issuance of fresh equity shares on a preferential basis as consideration, with no cash involved.
The acquisition of AOPL aims to strengthen the supply of critical materials, achieve strategic synergies, and enhance long-term shareholder value. AOPL, incorporated on December 1, 2025, is engaged in manufacturing pharmaceutical intermediates, industrial, and fine chemicals. Its turnover was ₹7,254.11 lakh as of March 31, 2026, and ₹4,554.36 lakh as of June 30, 2026. The total consideration for this acquisition is approximately ₹1,165,179,600, involving the issuance of up to 45,16,200 equity shares at ₹258 each.
Similarly, the acquisition of BLPL is intended to enhance operational efficiency, long-term competitiveness, and achieve strategic synergies. BLPL, incorporated on April 17, 2015, is involved in manufacturing, supplying, and exporting pharmaceutical drugs and intermediates, active pharmaceutical ingredients (API), and contract research and manufacturing services. Its turnover was ₹3,126.64 lakh as of March 31, 2026, and ₹1,152.78 lakh as of June 30, 2026. The aggregate consideration for BLPL is approximately ₹367,840,000, involving the issuance of up to 22,99,000 equity shares at ₹160 each.
Both acquisitions are classified as Related Party Transactions due to common promoters and directors but are being undertaken on an arm's length basis. The completion of these acquisitions is subject to customary closing conditions and is expected within 90 days from the signing of the respective agreements. The company plans to issue up to 8,58,83,617 equity shares in total through a preferential allotment for these transactions.
What to do with a filing like this
Anlon Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anlon Healthcare Limited. Read the original for the full detail.